Thrombin activatable fibrinolysis inhibitor and clot lysis time in women with recurrent miscarriage associated with the antiphospholipid syndrome.
Antiphospholipid syndrome patients with recurrent miscarriage have an impairment in fibrinolysis demonstrated by prolonged clot lysis time (CLT) that cannot be attributed to differences in thrombin activatable fibrinolysis inhibitor (TAFI) antigen levels. Patients with unexplained recurrent miscarriage have an impairment in fibrinolysis demonstrated by increased CLT, that can be at least partly explained by higher TAFI antigen levels.
Martínez-Zamora
M Angeles
MA
Institut Clínic of Gynecology, Obstetrics and Neonatology, Faculty of Medicine-University of Barcelona, Hospital Clínic, Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain.
Creus
Montserrat
M
Tassies
Dolors
D
Bové
Albert
A
Reverter
Juan Carlos
JC
Carmona
Francisco
F
Balasch
Juan
J
D000026:Abortion, Habitual / Q000097:blood* / Q000209:etiology; D000328:Adult; D016736:Antiphospholipid Syndrome / Q000097:blood* / Q000150:complications; D001777:Blood Coagulation / Q000502:physiology; D001780:Blood Coagulation Tests; D025901:Carboxypeptidase B2 / Q000032:analysis / Q000097:blood*; D016022:Case-Control Studies; D005260:Female; D005342:Fibrinolysis / Q000502:physiology; D006801:Humans; D011247:Pregnancy; D013997:Time Factors
D025901:Carboxypeptidase B2